PT-141 vs Melanotan 2 looks like a fair fight, but it is not. PT-141 was tested in about 1,250 women across two large trials, and it has a printed safety label (Trials). Melanotan 2 has never been approved as a medicine anywhere. In medical journals it turns up mostly as case reports of harm: moles that darken, new moles in bursts, and melanoma (Review).
What Melanocortin Peptides Are
Your body makes a signal called alpha-MSH. It tells skin cells to make pigment. It also reaches brain circuits that handle appetite and sexual desire.
That signal lands on a small family of switches called melanocortin receptors. Which switch a drug flips is what decides its effect. MC1R sits in the skin and drives pigment. MC3R and MC4R sit in the brain, where they shape appetite and desire (Review).
PT-141 vs Melanotan 2
Both drugs are factory copies of that signal. PT-141, also called bremelanotide and sold as Vyleesi, is a prescription injection for low sexual desire in women before menopause (Label). Melanotan II, usually written as MT-2 or melanotan 2, is the tanning peptide sold in vials online.
Here is the part sellers get wrong. PT-141 is not a clean brain-only drug. Its own label says it flips several melanocortin switches, and the skin-pigment one is the strongest (Label). Melanotan 2 flips all four active switches at once. That is why it tans skin and stirs arousal and nausea together (Review). The two are chemical relatives: bremelanotide came out of the Melanotan II family.
Then their paths split. One went into large trials. The other went into the gray market for research peptides. There, vials marked “not for human use” get injected anyway.
What PT-141 Actually Does
Two trials sit behind the drug, run together under the name RECONNECT. They enrolled 1,267 women before menopause who had hypoactive sexual desire disorder. That is low sexual desire that causes real personal distress, with no other cause behind it. A coin flip decided who got the drug and who got a matching dummy injection. Both trials ran 24 weeks (Trials).
The women injected 1.75 mg under the skin at least 45 minutes before sex. It is an as-needed drug, not a daily one (Label).
So what happened? The FDA’s own reviewers counted how many women improved enough to notice it. On the drug, about 1 in 3 reported a meaningful lift in desire. On the dummy injection, about 1 in 5 did (FDA Review). For distress, about half improved on the drug, against about 4 in 10 on placebo (FDA Review).
The gap is real, and it showed up in both trials. It is also modest, and the dummy injection did a lot of the work. The drug helps some women and does nothing for others.
The US approved bremelanotide in 2019 for that one group of women, and nobody else (Label). The label says it is not for women after menopause, not for men, and not for boosting performance. Approved does not mean strong. It means a regulator judged the benefit worth the risk in that narrow group.
The same label tells doctors to stop after 8 weeks if nothing has changed. It also caps use at 8 doses a month.
The Nausea Problem
In the trials, nausea hit 40 in every 100 women on the drug. On placebo it hit about 1 in 100 (Label).
Most of it came early. About 21 in 100 felt sick after the very first dose, and by later doses that was down to around 3 in 100. It usually started within an hour and lasted about two hours. Thirteen in every 100 needed anti-sickness medicine. A later study in 228 healthy women tested an anti-sickness pill taken beforehand. It did not help, so the label does not recommend it (Label).
Flushing affected about 20 in every 100 women, and headache about 11 in 100 (Trials). Side effects made 18 in every 100 stop treatment, against 2 in 100 on placebo. Nausea alone accounted for 8 of those, and nobody on placebo quit because of it. The whole research program covered 43 studies and about 3,500 people. Across all of it, nausea was the top reason people gave up on the drug (Review).
Each dose also nudges blood pressure up and heart rate down. The label reports a peak rise of about 6 points on the top blood pressure number, and 3 on the bottom one. That peak arrives two to four hours after a shot. Heart rate drops by up to 5 beats a minute. Both usually return to normal within 12 hours (Label).
A separate trial fitted 24-hour blood pressure monitors on 397 women. Most spikes were brief. About 88 in every 100 after the drug lasted 15 minutes or less, against 91 in 100 after placebo. Five spikes ran both high and long, and all five were in the drug groups (Trial). Small as that is, the label still draws a hard line. It bars the drug for anyone with uncontrolled high blood pressure or known heart disease (Label).
One side effect matters for what comes next. About 1 in 100 women on the drug developed patches of darker skin on the face, gums or breasts. In some of them it had not faded after stopping (Label). That is the pigment switch at work, inside a carefully dosed prescription drug.
Melanotan 2 and Your Moles
Melanotan 2 pushes that same pigment switch much harder, and the mole reports follow.
A 2017 review gathered the published cases. It found repeated reports of moles that darkened and new moles that appeared, some of them odd-looking. Four separate reports described a melanoma that grew out of an existing mole during or shortly after melanotan use (Review).
Speed is the part people underestimate. In one report, new moles appeared and old ones darkened within 24 hours of a single injection (Case report). The drug had been bought illegally, so nobody checked what was in it.
Another case involved a 20-year-old woman with fair skin. She finished a course of three to four weeks. Three months later doctors removed a black spot from her buttock, and it was melanoma (Case report). She had been using sunbeds alongside the injections, so nobody can untangle which caused what.
These are case reports, single stories written up one at a time. They cannot tell you how often any of this happens. The reviewers also say the proof of cause is not there (Review).
The worry still stands, though. Doctors catch early melanoma by watching moles change: a new one, a darker one, an odd shape. A drug that changes moles on purpose scrambles the exact signal they look for. A tan also tends to invite more time in the sun. That is two risks stacked on top of each other.
The approved cousin in this drug family shows the same effect. Afamelanotide’s label tells doctors to check the patient’s whole skin twice a year. The reason is that the drug darkens existing moles and freckles (Label). That is a supervised medicine with a dermatologist attached. A vial from a website comes with nobody watching your skin.
Harms Beyond the Tan
A 39-year-old man wanted a winter tan. He injected 6 mg of Melanotan 2 that he had bought online. That was six times the starting dose he had been given. Two hours later he was in the emergency room, sweating, anxious and aching all over. His heart ran at 130 beats a minute and peaked at 146. His muscle was breaking down and his kidneys were struggling. He spent three days in intensive care on fluids before his blood tests came back down (Case report). Chemists later confirmed the injected liquid really was Melanotan 2.
Then there is priapism, an erection that will not go down and turns painful. In one reported case, a 55-year-old man had injected the peptide for over six years without trouble. After one ordinary 2 mg dose he reached hospital 30 hours into an erection. Bedside drugs and drainage failed, and he needed surgery. Fifteen weeks later he had new erectile dysfunction and scarring, and the usual pills did nothing (Case report). A second published case also needed emergency drainage. A month later that man had still not recovered erectile function (Case report).
None of this is a surprise from the biology. The first human study of Melanotan 2, in 1996, gave it to three healthy men. Two of them tanned. Spontaneous erections turned up as well, and they lasted one to five hours after a dose. The report never says how many of the three men had them. Mild nausea came with most doses (Study). The tan does not seem to arrive on its own.
The human trial record is tiny. The largest published work gave Melanotan 2 to 20 men with erectile problems and watched them for six hours (Trial). Add the three men from the 1996 pilot, and the whole published record is roughly two dozen people (Study). Nothing bigger has been published since.
The vial is its own problem. Researchers bought injectable Melanotan 2 from three online shops. Every shop promised 10 mg per vial. The real amounts ran from about 4 mg to under 9 mg, so not one vial held what it claimed. Vials from two of the three shops also carried impurities the chemists could not identify (Study).
A forensic lab later tested a vial seized in a police raid. The label said 10 mg. Inside was 8.7 mg of powder, and that powder was only about a third real peptide. Actual dose: roughly a quarter of what the label promised (Study).
The supply chain has worse problems than wrong doses. A Belgian team tested 27 vials of the most commonly faked peptides, bought from three illegal online pharmacies. Seven broke the safety limits for metals in an injected drug: six for arsenic, one for lead (Study). The report never says which peptide sat in each contaminated vial. So the metals cannot be pinned on Melanotan 2 itself, only on the same shops that sell it.
These products are easy to find. A dermatology team searched Google in December 2020 and screened the first 100 results. They counted 35 shops selling this family of peptides. Most labeled them for research use only while still advertising the tan (Study).
Where the Rules Stand
The US picture moved during 2026. Here is where it sits in August.
Bremelanotide is a prescription medicine, approved in 2019 for one narrow group of women (Label). Melanotan 2 is approved as a medicine nowhere in the world. Afamelanotide is the only copy of this hormone that has ever cleared a regulator (Review).
Compounding pharmacy rules shifted this year, and plenty of secondary write-ups got the details wrong. In April 2026 the FDA moved 12 peptides out of a safety-concern category, and Melanotan 2 was one of them. The people who had nominated those peptides pulled the nominations. That step did not make it lawful to compound the substance (Analysis).
On 23 and 24 July 2026 the FDA’s compounding advisory committee met and voted on seven peptides. The official meeting notice names them: BPC-157, KPV, TB-500, MOTS-C, emideltide, Semax and epitalon (Notice). Neither PT-141 nor Melanotan 2 appears anywhere in that notice, whatever some summaries say. The committee backed six of the seven. Even those six cannot be lawfully compounded until the FDA finishes writing the rule (Analysis).
Melanotan 2’s own review was pushed to a meeting due before the end of February 2027 (Analysis). So at the time of writing, that committee has not voted on it.
PT-141 was not on the July agenda, for a simple reason. The list exists for substances that are not already ingredients in an approved drug (Notice). Bremelanotide is the ingredient in Vyleesi, so it does not belong there. That also means a vial of “PT-141” from a website is not the pharmacy product. Nobody has tested what is inside it.
One last piece of housekeeping. Afamelanotide, sold as Scenesse, is an approved melanocortin drug, and it is nothing like a tanning peptide. It is a 16 mg implant that a trained provider places under the skin every two months. It treats erythropoietic protoporphyria, an inherited condition where sunlight causes severe pain (Label). Its approval says nothing about Melanotan 2.
Frequently Asked Questions
PT-141 vs Melanotan 2: are they the same drug?
No. They are chemical relatives from the same peptide family, and both act on melanocortin receptors. PT-141 is a prescription drug tested in about 1,250 women across two large trials (Trials). Melanotan 2 has never been approved. The largest published study of it gave the peptide to 20 men for six hours (Trial).
Is melanotan 2 legal to buy?
Melanotan 2 is not approved as a medicine anywhere, so it cannot legally be sold for human use (Review). Sellers list the vials online as research chemicals instead, which is how the market sidesteps that (Study). In the US it is not on the compounding pharmacy list either. Its review was pushed back to a meeting due before the end of February 2027 (Analysis).
Does melanotan 2 cause skin cancer?
Nobody can say that with certainty, because the evidence is case reports rather than population studies. Moles do darken and new ones do appear. Four published reports also describe a melanoma that started in a mole during or soon after use (Review). The practical worry stands either way: a drug that changes moles may hide the earliest sign doctors look for.
Does PT-141 work for men?
The approved label says it is not for them. Bremelanotide is licensed only for women before menopause whose low sexual desire causes them real distress. The label says plainly that it is not for men (Label). Older and much smaller work did give melanocortin peptides to men, and erections followed. That study was 20 men watched for six hours (Trial).
How long does PT-141 take to work?
It is taken before sex rather than daily. The label advises an injection at least 45 minutes beforehand (Label). Whether it helps at all takes longer to judge. The label sets an 8-week checkpoint: if desire has not improved by then, the advice is to stop.
Key Takeaways
- PT-141’s benefit is real but modest. About 1 in 3 women improved on the drug, against about 1 in 5 on placebo. That was across two trials of roughly 1,250 women (FDA Review).
- Nausea is the main cost. It hit 40 in every 100 users, 13 in 100 needed anti-sickness medicine, and 18 in 100 quit over side effects (Label).
- It is off limits for some hearts. Each dose briefly raises blood pressure, so the label bars use with uncontrolled high blood pressure or known heart disease (Label).
- Melanotan 2 changes your moles. In one report moles darkened and new ones appeared within 24 hours of a single injection. Melanoma turns up in four published cases (Review).
- Nobody knows what is in the vial. Vials labeled 10 mg held about 4 to 9 mg. Two of the three shops tested also sold vials with impurities nobody could identify (Study).
- Afamelanotide is a different drug. Scenesse is an implant for a rare light-sensitivity disease, and its label asks for a full skin check twice a year (Label).
Weigh the Tan Against the Risk
These two peptides get grouped together in forum posts and vendor listings. They should not be. One has 1,250 women behind it, a dose ceiling, a printed list of side effects and a doctor attached. The other has a handful of case reports and a vial whose contents are a guess.
If low sexual desire is the problem, that is worth raising with a clinician. PT-141 is a real drug with real tradeoffs. A clinician can help you weigh the nausea and the blood pressure against a modest benefit. Some women find it useful. Many stop taking it.
If a tan is the goal, the answer is simpler. No vial bought online is worth losing the ability to read your own moles.
This article is for educational purposes and is not medical advice. Talk to a qualified clinician before changing your health regimen.
Same hormone, same receptors, very different evidence behind them. It is worth knowing which one you are holding.
Bio-Hacking.Blog 
Leave a comment